bendamustine

The patient was treated with six cycles of rituximab-bendamustine, resulting in complete regression of the nasopharyngeal mass and reduction in splenomegaly, with minimal residual lymphadenopathy and good clinical and biological tolerance. This case highlights the importance of considering CLL in the differential diagnosis of nasopharyngeal masses and emphasizes the role of combined imaging, histology, and immunophenotyping in establishing an accurate diagnosis and guiding appropriate management.

P1/2, N=45, Completed, Artiva Biotherapeutics, Inc. | Active, not recruiting --> Completed | Trial primary completion date: Aug 2024 --> Oct 2025

The phase 3 CLL13/GAIA trial assesses three time-limited combinations: venetoclax-rituximab (RV), venetoclax-obinutuzumab (GV), and venetoclax-obinutuzumab-ibrutinib (GIV) compared to chemoimmunotherapy (CIT). Fit patients with CLL without TP53 aberrations were randomized between six cycles of CIT (fludarabine-cyclophosphamide-rituximab [FCR], bendamustine-rituximab [BR]) or 12 cycles of RV, GV or GIV (GIV: ibrutinib continuation until cycle 36 if measurable residual disease [MRD] at months 12/15)...In the GIV arm, clinically relevant QoL improvements occurred later (month 15, after the end of treatment in most patients) than with GV/RV, likely due to a higher treatment-related symptom burden. The trial is registered at clinicltrial.gov with the identifier, NCT02950051.

P2, N=49, Active, not recruiting, Fondazione Italiana Linfomi - ETS | Recruiting --> Active, not recruiting

Compared with remdesivir and molnupiravir, ensitrelvir achieves higher rates of SARS-CoV-2 antigen clearance and a more favorable viral shedding profile. Case Presentation: A 67-year-old Japanese man with follicular lymphoma had received obinutuzumab plus bendamustine, followed by obinutuzumab maintenance therapy...Three months prior to the current admission, the patient developed coronavirus disease 2019 (COVID-19) and was treated with a 10-day course of remdesivir and dexamethasone... Ensitrelvir may be an effective therapeutic option for the treatment of persistent or refractory COVID-19 in immunocompromised patients. Clinicians should recognize that patients treated with obinutuzumab may remain immunosuppressed for several years after therapy.

P3, N=0, Withdrawn, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | N=300 --> 0 | Not yet recruiting --> Withdrawn

P1/2, N=39, Recruiting, Tr1X, Inc.

Chemoimmunotherapy for malignant lymphoma, including corticosteroids, rituximab (R), and Bruton's tyrosine kinase inhibitors, depletes normal lymphocytes and disrupts lymphocyte function...We treated a case of relapsed malignant lymphoma, infected with triple infections, Campylobacter coli, Cytomegalovirus, and SARS-CoV-2, during treatment with epcoritamab after standard chemoimmunotherapies, including R-cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP), and R-bendamustine...His treatment for infections included remdesivir, meropenem, and ganciclovir...Epcoritamab can demonstrate long-standing B-cell depletion; however, a long-term influence on T cells is still elusive. This case suggested that we should pay special attention to patients with B-cell manipulating therapy including R, CAR-T, and BiTEs such as epcoritamab.

In patients with cBTKi-pretreated relapsed/refractory (R/R) CLL, the BRUIN-CLL-321 trial demonstrated improved progression-free survival (PFS) and time to next treatment (TTNT) compared with idelalisib/rituximab or bendamustine/rituximab, accompanied by a favorable tolerability profile. Data from randomized phase III BRUIN-CLL-313 and BRUIN-CLL-314 trials demonstrate the superiority of pirtobrutinib over chemoimmunotherapy in untreated patients and non-inferiority to ibrutinib in untreated patients or in patients with R/R disease who had no prior exposure to cBTKis. These data are not sufficient to justify a change in clinical practice; however, they lay the groundwork for a potential future repositioning of pirtobrutinib from the treatment of R/R CLL to earlier lines of therapy. In this review, we address a range of current and prospective aspects of pirtobrutinib-based therapies: (1) the strengths and limitations of the trial datasets; (2) the biological rationale for frontline noncovalent BTK inhibition; (3) sequencing trade-offs; and (4) prospective scenarios, including combination strategies and time-limited regimens.

P3, N=822, Recruiting, Regeneron Pharmaceuticals | N=462 --> 822 | Trial completion date: Nov 2031 --> Nov 2029 | Active, not recruiting --> Recruiting

P3, N=590, Active, not recruiting, BeiGene | Trial completion date: Sep 2026 --> Oct 2027

The patient achieved a Complete Metabolic Response following Bendamustine-Rituximab therapy. This case underscores the utility of PET/CT in detecting occult systemic disease and defines a unique, indolent clinical variant of muscular MALT lymphoma.